Anlotinib combined with nab-paclitaxel and cisplatin as neoadjuvant treatment (NAT) for esophageal squamous cell carcinoma (ESCC): Update results of a single-arm, phase. clinical trial.

被引：0
|
作者：
Zhang, Yan-Feng
Li, Xiao-Bing
Hong, Yong-Gui
Li, Xiao-Ming
Liang, Wei-Min
Zheng, Zhi-Xin
Yang, Guang-Yi
Wen, Yan-Yan
Cao, Heng
Wu, Wei-Long
Su, Wen-Zhong
机构：
[1] Anyang Tumor Hosp, Anyang, Peoples R China
[2] Anyang Tumour Hosp, Anyang, Peoples R China
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
366
引用
收藏
页码：366 / 366
页数：1
相关论文
共 50 条
  • [1] Anlotinib combined with nab-paclitaxel and cisplatin as neoadjuvant treatment for esophageal squamous cell carcinoma (ESCC): A single-arm, open-label phase II clinical trial.
    Zhang, Yan-Feng
    Hao, An-Lin
    Hong, Yong-Gui
    Li, Xiao-Ming
    Liang, Wei-Min
    Zheng, Zhi-Xin
    Yang, Guang-Yi
    Guo, Xiao-Feng
    Wen, Yan-Yan
    Cao, Heng
    Le, Cheng
    Song, Hua-Jie
    Su, Wen-Zhong
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16) : E16015 - E16015
  • [2] Update results of anlotinib combined with nab-paclitaxel and cisplatin as neoadjuvant treatment for esophageal squamous cell carcinoma (ESCC): A single-arm, open-label phase II clinical trial
    Zhang, Y-F.
    Li, X-B.
    Hong, Y-G.
    Li, X-M.
    Liang, W-M.
    Zheng, Z-X.
    Yang, G-Y.
    Wen, Y-Y.
    Cao, H.
    Wu, W-L.
    Su, W-Z.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S1120 - S1120
  • [3] Update results of anlotinib combined with penpulimab and nab-paclitaxel as first-line treatment for advanced esophageal squamous cell carcinoma (ESCC): A single-arm, open-label phase II clinical trial.
    Chang, Zhiwei
    Liu, Xiao-Lei
    Yu, Dan-Dan
    Han, Hui-Qiong
    He, Jian
    Wang, Rui-Rui
    Jia, Yong-Xu
    Yan, Jie
    Qin, Yanru
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [4] Anlotinib combined with penpulimab and nab-paclitaxel as first-line treatment for advanced esophageal squamous cell carcinoma (ESCC): A single-arm, open-label phase II clinical trial.
    Chang, Zhiwei
    Wang, Rui-Rui
    Liu, Xiao-Lei
    Yu, Dan-Dan
    Han, Hui-Qiong
    He, Jian
    Qin, Yanru
    JOURNAL OF CLINICAL ONCOLOGY, 2025, 43 (4_SUPPL) : 367 - 367
  • [5] TQB2450 plus anlotinib combined with paclitaxel and cisplatin as first-line treatment of advanced esophageal squamous cell carcinoma (ESCC): Update results of a single-arm, multicenter phase. trial
    Wang, Junsheng
    Li, Ning
    Guo, Yanzhen
    Cheng, Yufeng
    Li, Baosheng
    Luo, Su-xia
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [6] Anlotinib combined with paclitaxel and cisplatin as neoadjuvant treatment for esophageal squamous cell carcinoma (ESCC).
    Jiang, Gongqian
    Wang, Guolei
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 : 409 - 409
  • [7] Anlotinib combined with penpulimab and nab-paclitaxel as first-line treatment for advanced esophageal squamous cell carcinoma (ESCC): A single-arm, open-label phase II clinical trial
    Chang, Zhiwei
    Liu, Xiao-Lei
    Yu, Dan-Dan
    Han, Hui-Qiong
    He, Jian
    Wang, Rui-Rui
    Qin, Yan-ru
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (3_SUPPL) : 340 - 340
  • [8] Neoadjuvant anlotinib combined with penpulimab for resectable locally advanced esophageal squamous cell carcinoma (ESCC): A prospective, single-arm, phase II trial.
    Chen, Yueyun
    Ding, Zhen-Yu
    Yuan, Yong
    Yang, Yu-Shang
    Lin, Zhen
    Tian, Jiangfang
    Liu, Ting
    Yue, Zheng
    Shi, Hua-Shan
    Hu, Yang
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (3_SUPPL) : 352 - 352
  • [9] Update results of paclitaxel and cisplatin in combination with anlotinib as first-line regimen for advanced esophageal squamous cell carcinoma (ESCC): A multicenter, single-arm, open-label phase II clinical trial.
    Wang Junsheng
    Luo Suxia
    Li Ning
    Wu Tao
    Hong Yonggui
    Guo Yanzhen
    Cheng Yufeng
    Li Baosheng
    Tan Bingxu
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (03)
  • [10] Update results of paclitaxel and cisplatin in combination with anlotinib as first-line regimen for patients with advanced ESCC: A multicenter, single-arm, open-label phase. clinical trial.
    Wang, Junsheng
    Wu, Tao
    Luo, Suxia
    Li, Ning
    Hong, Yonggui
    Guo, Yanzhen
    Cheng, Yufeng
    Li, Baosheng
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (04)
12345